Ryerson (NYSE: RYI) CFO sells 4,972 shares under 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Ryerson Holding Corp's Executive Vice President and CFO, James J. Claussen, reported selling 4,972 shares of common stock on February 3, 2026 at $30 per share.
After this transaction, he beneficially owned 74,284.3365 shares. The sale was made under a pre-established Rule 10b5-1 trading plan adopted on October 30, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 4,972 shares ($149,160)
Net Sell
1 txn
Insider
Claussen James J
Role
Executive Vice President & CFO
Sold
4,972 shs ($149K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock (par value $0.01 per share) | 4,972 | $30.00 | $149K |
Holdings After Transaction:
Common Stock (par value $0.01 per share) — 74,284.337 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What insider transaction did Ryerson (RYI) report for James J. Claussen?
Ryerson reported that Executive Vice President and CFO James J. Claussen sold 4,972 shares of common stock on February 3, 2026 at $30 per share. The filing shows this as an open market sale coded as transaction type S.
Was the Ryerson (RYI) CFO’s stock sale made under a Rule 10b5-1 trading plan?
Yes. The footnote explains that the sale was effected under a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. Such plans pre-schedule trades according to predetermined instructions.
What role does the insider in this Ryerson (RYI) Form 4 hold at the company?
The reporting person on the Form 4, James J. Claussen, is identified as an Executive Vice President & CFO of Ryerson Holding Corp. The filing does not mark him as a director or a 10% beneficial owner.
Did the Ryerson (RYI) Form 4 report any derivative securities transactions?
No derivative securities transactions are reported. The section for derivative securities lists no acquired or disposed instruments. The only reported activity is the non-derivative common stock sale of 4,972 shares at $30 per share on February 3, 2026.